By Draper
Draper has a 25+ year legacy focused on development of in vitro human tissue Microphysiological Systems (MPS). We employ advanced, cross-cutting solutions to improve our understanding of how CRBNE threats affect the body and to predict the safety and effectiveness of drugs, vaccines, and antibody-based treatments. Draper advancements in the field have resulted in MCM evaluation solutions that leverage human tissue MPS (or organ-on-chip) platforms, immune system models, molecular and cellular assays, omics-based technologies, and advanced analytical methods. These innovations enable in-depth assessment of threat agents and MCM interventions. Draper employs a suite of capabilities and technologies to assess CBRNE threats, enabling assessment of the host response to injury, infection, disease progression, and inflammation. These tools also enable the evaluation of repurposed or novel MCMs for efficacy, biomarker discovery, correlates of immune protection, and toxicology and safety prediction. We aim to develop streamlined and prognostic MCM solutions that can complement or replace animal models in CBRNE research and testing and enable the evaluation of MCMs for CBRNE threats. This goal directly aligns with long-term requirements established by the U.S. Congress and the FDA. Drug and MCM candidates often fail to demonstrate adequate efficacy and safety as the FDA regulatory process progresses from animal models to human clinical trials. Additionally, the accepted preclinical animal models and human clinical trials have embedded time and cost constraints that affect MCM development timelines for critical CBRNE threats. To date, we have fielded 10 distinct single-organ tissue models, separate models for organoids, solid tumor, and revolutionary multi-organ platforms to model the holistic and interconnected function of human organ systems. Designed for seamless integration into standard laboratory equipment and drug evaluation pipelines, our technologies maximize flexibility and throughput. With parallel, integrated sensors, our platforms deliver far more high-quality data than other preclinical models, making preclinical testing for drug development more predictive and enabling novel drug discovery avenues.
